Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
Boston startup Entrega is developing a novel drug-delivery capsule that could give the company a foothold in a $200 billion arena just begging for more needle-free options, paving the way for the more elegant delivery of treatments for diseases such as Parkinson's, cancer and arthritis.
The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.
Kala Pharmaceuticals received a grant from the Cystic Fibrosis Foundation to demonstrate that the company's mucosal-barrier-penetrating nanoparticle can do the same across bacterial biofilms, a symptom of cystic fibrosis.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Mucosal delivery company Kala Pharmaceuticals has welcomed Guillaume Pfefer, ex-general manager of Sanofi Pasteur Mexico, as its new president and CEO. Kala's co-founder, Justin Hanes, has published data on the company's mucosal-penetrating products (MPPs) in Science Translational Medicine.
The startup biotech Kala Pharmaceuticals has taken another step forward in its journey to the clinic. The Waltham, MA-based developer of mucus-penetrating particle treatments--one of Robert Langer's portfolio of startups--has wooed Gillaume Pfeffer into the top spot.
An upstart biotech company with intriguing new formulation technologies and a roster of influential backers has rounded up $6.2 million in additional seed capital.
Kudos to Kala Pharmaceuticals. The early-stage developer of treatments designed to reach mucosal organs just brought in an additional $6.2 million in equity financing to help carry various preclinical programs to human clinical trials.